Introduction
Anticipation is a phenomenon characterized by decreasing age at onset and/or increasing severity of symptoms of a disease in successive generations within a pedigree. Although it was viewed with skepticism for most of the last century as a possible result of ascertainment bias, the last decade has witnessed the recognition of trinucleotide repeat expansion as a molecular cause of this phenomenon in several human hereditary diseases (McInnis 1996) . This has 1990 and 2000, and are listed in the Database of Germline p53 Mutations (Sedlacek et al. 1998) . Our results lend credence to the notion that anticipation may indeed be a feature of the Li-Fraumeni syndrome.
Subjects and methods

Set of families
The December 2000 update of the Database of Germline p53 Mutations (Sedlacek et al. 1998 , http://www.lf2.cuni.cz/ projects/germline_mut_p53.htm) was used as a source of the data. The database contained reports on 162 independent germline TP53 mutations in 162 families or isolated patients. In total, there were reports on 689 individuals (including 62 unaffected carriers) and 803 tumors. Of these, 549 individuals with known age at onset of the first tumor were included in the analysis. For analytical purposes, the youngest generation was always assigned the letter Z in each family in the database, the second-youngest generation was assigned Y, the third-youngest generation was assigned X, etc. The generational membership was, however, not fixed to the age at onset (for example, an isolated individual with tumor onset at 72 years was assigned generation Z). In case an individual suffered from more than one tumor during his or her lifetime, only the age at onset of the first tumor was considered.
Data were imported from the Excel table into an Access database system. Data relevant for each particular analytical approach were extracted from the Access tables and processed using the SPSS software package (Norusis 1994 ).
Comparison of the mean age at onset between generations
Families were subdivided into five classes according to the number of generations reported for each family. The mean ages at onset for each generation were calculated separately for one-, two-, three-, four-, and five-generation families. In the same way, both sexes were then analyzed separately. Finally, two types of germline mutations (missense versus truncating [nonsense, frameshift, and splicing]) were also separately studied. The statistical significance of the differences in the mean age of onset between generations, between sexes, and between mutation types was tested using univariate analysis of variance, or analysis of variance with two factors, respectively. The significance of sex or mutation type differences in one-generation families was analyzed using the t-test.
Intergenerational pairwise comparisons of age at onset
To reduce potential sampling biases, we used four different sampling schemes for pairwise comparisons of the age at onset in two-to five-generation families (McInnis et al. 1993 ).
1. Random pairs consisted of one randomly selected affected individual from one generation and one randomly selected affected individual from the previous generation of the same family. This sampling is statistically conservative. 2. All possible pairs were formed by pairing each affected individual from one generation with all affected individuals from the previous generation within a family. Inclusion of childless individuals in schemes 1 and 2 reduces the bias from reduced fertility of severely affected family members, and scheme 2 tests for robustness of scheme 1. By including affected siblings of parents of affected children, the study of nontransmitting pairs should reduce the spurious anticipation bias (Hoh et al. 2001 ). 3. Random transmitting pairs consisted of one randomly selected affected parent and one of his or her randomly selected affected children. This scheme is statistically conservative and represents the most direct test of anticipation. 4. All possible transmitting pairs were formed by pairing each affected parent with each of his or her affected children. Similar to the testing of scheme 2 for scheme 1, scheme 4 tests for robustness of scheme 3.
One pair was selected in schemes 1 and 3 from each two successive generations of a family. Pairs that included a child in which both parents were affected by a tumor (possible bilineal transmission) were excluded from schemes 3 and 4. Mean differences in ages at onset were calculated for the parent and offspring generations and compared using the Wilcoxon signed rank test.
All four schemes of pairwise comparisons were performed with the whole dataset and then with different subsets of data. First, only those pairs were included in which the age at onset in the offspring was after 25 years of age (subset offspring Ͼ 25 years), to eliminate individuals with very early onset of cancer in the offspring generation (McInnis 1996) . Second, pairs were only included in which the age at onset in the parent was less than 28.8 years (subset parent Ͻ 28.8 years), which was the mean age at onset in the whole dataset. This measure was aimed at the elimination of ascertainment or observational bias (Han and Peschel 2000) .
In addition, sampling schemes 3 and 4, using transmitting pairs, were applied to further data subsets. Pairs were separately analyzed in which the offspring belonged to generations Y, X, and W and the parent was affected at an age younger than 25, 50, and 75 years, respectively (subset generations 25 years). Considering intergeneration difference of 25 years, this selection should include pairs in which both the parent and his or her offspring were followed for the same time period (about 25, 50, and 75 years, respectively) (Imamura et al. 1998 ). To test for a possible effect of the mode of parental transmission on the difference in the age at onset, we separately analyzed pairs with female or male sex of the transmitting parent (subsets mothers, fathers). Similarly, we examined the data separately according to the sex of the offspring (subsets daughters, sons). The signifi-cance of the influence of sex of the parent or of the offspring on the difference in the age at onset between generations was analyzed using analysis of variance of repeated measures.
Results
Comparison of the mean age at onset between generations
The mean age at onset in different generations for the whole dataset is listed in Table 1 . The same calculation was also performed separately for males and females, and for missense and truncating mutations (data not shown). The mean age at onset of the first cancer is always lower in the generation of offspring than in the generation of parents for any two successive generations in any dataset, and the difference in the mean age at onset between generations in multiple-generation families is always highly significant (P Ͻ 0.0005). There is no significant difference in the age at onset between sexes for the one-, two-, three-, and fourgeneration families (P ϭ 0.26, 0.106, 0.297, and 0.265, respectively). For the five-generation families, the sex difference is of borderline significance (P ϭ 0.047), with the age at onset being higher in females. The set of data for fivegeneration families is not reliable, however, because of small numbers. Similarly, the influence of the mutation type on the age at onset is significant in one-generation families, with the truncating mutations being associated with earlier age at onset (P ϭ 0.009), but there are only three mutations in this category among one-generation families. There is no significant difference in the age at onset of cancer and anticipation between mutation types for the two-, three-, and four-generation families (P ϭ 0.619, 0.070, and 0.100, respectively), although the trend of missense mutations being associated with later age at tumor onset than are truncating mutations can be repeatedly observed. There are no missense mutations in five-generation families.
Intergenerational pairwise comparisons of age at onset
The results of pairwise comparisons using sampling schemes 1-4 are listed in Tables 2-5. The fraction of pairs showing anticipation exceeds 50% for every sampling scheme and all subsets of data. Similarly, the mean age at onset in the offspring is always lower than that in the parent. As expected, both the fraction of pairs showing anticipation and the mean difference in the age at onset between generations decrease in subsets offspring Ͼ 25 years, parent Ͻ 28.8 years, and generations 25 years compared with the whole unselected dataset. The difference is always statistically significant with the exception of subset generations 25 years in scheme 3 (P ϭ 0.09). The age difference in subset generations 25 years in scheme 4 is weakly significant (P ϭ 0.024). The subset generations 25 years consists, however, of a very small number of pairs in each of these two schemes (11 and 26, respectively). In addition, the transmitting pairs were analyzed separately according to the sex of the parent (subsets mothers, fathers, Tables 4-5) or sex of the child (subsets daughters, sons, data not shown). The fraction of pairs showing anticipation always exceeds 50% and the mean difference in age at onset in the offspring and in the parent is always highly significant. For random transmitting pairs, no significant influence of either the sex of the parent or the sex of the child on the mean difference in the age at onset between generations was found. For all possible transmitting pairs, significant influence of the sex of the parent on the mean difference in the age at onset was found (P ϭ 0.039), with the paternal transmission associated with increased mean age difference between generations (Table 5) . No influence of the sex of the offspring on the mean difference in the age at onset was found.
Discussion
A significant decrease in the age at onset of cancer between successive generations in pedigrees with germline TP53 mutations was demonstrated in this study. This was ob- served not only for the mean ages at onset calculated for different generations, but also in different schemes of pairwise comparisons. Our analyses therefore suggest the existence of anticipation resulting in increasingly earlier age at onset of cancer in successive generations of carriers of germline TP53 mutations. We attempted to minimize all possible biases by using multiple analytical approaches, several sampling schemes, and separate analyses of several subsets of data selected using various conservative assumptions. One possible ascertainment bias is the underrepresentation of families with early-onset cases (before reaching the reproductive age) in the older generation and late occurrence in the younger generation because of reduced fertility in the older generation. To avoid this bias, we removed all individuals with onset under the age of 25 years from the offspring generation and repeated the statistical analysis (subset offspring Ͼ 25 years). Within this subset, the conditions for both generations are more comparable. To further reduce the bias resulting from impaired fertility, we examined not only the parent-offspring pairs, but also the nontransmitting pairs (random pairs, all possible pairs) (McInnis 1996; McInnis et al. 1993) .
To avoid the underrepresentation of families with earlyonset cases in the older generation and late-onset cases in the younger generation because of the time of ascertainment being too short for the younger generation to develop symptoms, we also performed the analysis for a subset of individuals in which the age at diagnosis in the parents was less than the mean age at onset in the whole dataset (subset parent Ͻ 28.8 years) (Han and Peschel 2000) . In an even more stringent selection of pairs for the analysis (generations 25 years), we selected only those transmitting pairs in which the offspring belonged to generation Y (or X, or W) and the age at onset in the parent was less than 25 years (or 50, or 75 years, respectively) (Imamura et al. 1998) . Assuming an intergeneration span of 25 years, the offspring can be expected to be followed for at least 25 (or 50, or 75 years, respectively) , and this time is longer than the age at onset of cancer in the parents.
All subsets tested showed similar patterns suggestive of anticipation in the age of cancer onset in the pedigrees, and the age differences were statistically significant. Even in the most stringent subset generations 25 years, in which the number of pairs was only 11 and 26 for random transmitting pairs and all possible transmitting pairs, respectively, the difference remained near significant (Tables 4-5) .
Another possible bias that may mimic anticipation can result from shared environmental factors. We consider this less likely because the affected individuals within and between families in the dataset are widely distributed geographically and across time. Bilineality is unambiguously proven at the molecular level only in one family in the database and its possible influence was suppressed by the exclusion of all offspring with both parents affected from the pairwise comparisons. Possible preferential reporting of families with simultaneous onset in a parent and his or her offspring or of families with unusually early onset in the child and the fact that our study is based on published reports rather than on a regularly updated registry represent two additional potential biases. To avoid all biases completely, one would need a prospectively obtained case study on a very large population over a period of several generations (Wiernik et al. 2000) . Such a study is rather impractical, however, because of the very low incidence of the disorder and the length of the time period required. Additionally, the Li-Fraumeni syndrome was recognized as late as 1968, and germline TP53 mutations were recognized as the etiological cause of the disorder only in 1990.
Our study is a first attempt to statistically evaluate the suspected anticipation in the Li-Fraumeni syndrome. However, further data collection and analyses are needed to decide unambiguously about this phenomenon. If anticipation in age at onset really exists in the pedigrees carrying germline TP53 mutations, it should be based on a biological mechanism involving the p53 protein. It is tempting to speculate that this mechanism might be related to the recently recognized role of p53 in genome stability (ArandaAnzaldo et al. 1999; Murphy et al. 2000; Lin et al. 2000; Dahm-Daphi 2000) . The gain-of-function germline mutations and/or reduced dosage of the normal TP53 gene expression might cause some kind of cumulative damage to the genome of the cells in the germ line, which could then result in an even more increased level of susceptibility to cancer in successive generations. Indeed, it will only be the identification and deciphering of such a biological mechanism that will definitively solve the question of anticipation in this disorder.
If anticipation in Li-Fraumeni syndrome is unambiguously proven, this will have important practical consequences for genetic counselling and testing and for the timing of preventative screening programs for individuals at risk. According to the present recommendations for the care of affected families, testing of young children should not be offered routinely (Li et al. 1992; Varley et al. 1997) . Furthermore, possible influence of paternal or maternal transmission or the type of mutation on the age at onset in the offspring cannot be fully excluded.
